Overall verdict
Neutral
5.3/10
1-year performance
+45.53%
Score breakdown
Up 45.5% over 1 year, 93% of the 52-week range.
Strongest: Financial strength 7.8/10. Weakest: Profitability 2.4/10.
26 analysts, target +0.0% vs the price.
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination ; individual Medicare stand-alone prescription drug products (PDP) ; group Medicare advantage and Medicare stand-alone PDP ;
Medicare supplements ; specialty and ancillary insurance comprising dental, vision, life and disability ; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands ;
a management services organization ; CenterWell Home Health, a home health provider ; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
James Rechtin
Founded
1961
Employees
67 060
Revenue / employee
1.9M USD
Next earnings
November 6, 2026
Institutional holders
- Dodge & Cox9.97%
- BlackRock, Inc.9.49%
- VANGUARD CAPITAL MANAGEMENT LLC7.15%
- VANGUARD PORTFOLIO MANAGEMENT LLC5.30%
- STATE STREET CORP4.97%
- PZENA INVESTMENT MANAGEMENT LLC4.01%
- EAGLE CAPITAL MANAGEMENT LLC3.50%
- Sessa Capital IM, L.P.3.40%
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/3.10%
- Other institutions56.66%
926 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
428.88 USD
52-week low
163.11 USD
1-year performance
45.53%
Rising
Year-to-date performance
46.38%
Rising
Drawdown
-4.40%
Near its high
Position in the 52-week range
93% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.6 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Humana | 148 283 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.6 times as much as the world ETF.
- Worst fall:-75 % between November 2022 and March 2026. 10,000 € placed at the top fell to 2 548 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Humana earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Humana: 148 283 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 280.00 USD - 493.10 USD (2 methods agree)
The price implies growth of 6.88% per year; the company grows at -10.00%.
Net margin 0.9%, ROIC 4.1%, ROE 6.8%.
Net margin
0.88%
Low
Sector 1.68%|S&P 12.97%
Gross margin
—
Return on equity (ROE)
6.83%
Low
Sector 10.87%|S&P 16.52%
Return on invested capital (ROIC)
4.13%
Low
Free cash flow margin (FCF)
1.34%
Low
Profit-to-cash conversion (FCF conversion)
1.52x
Fair
Margin stability
1.3 pts
Very steady
Revenue to net income
Growth
4.4/10Revenue up 26.2% over 1 year, 10.9% a year over 5, EPS -17.2% a year over 5.
Revenue (trailing 12 months)
146Md USD
Revenue growth (1y)
26.18%
Hyper-growth
Revenue growth (3y)
39.59%
Solid
EPS growth (1y)
26.93%
Solid
EPS CAGR (5y)
-17.23%
Declining
EPS revisions (3 months)
3.51%
Revised up
Valuation
3.2/10P/E 38.8x, forward P/E 57.3x, EV/EBITDA 11.4x, PEG 1.44. The multiple sits in the 97th percentile of its own 5-year history.
P/E (TTM)
38.8x
Expensive
Sector 26.2x|S&P 23.0x
Forward P/E
57.3x
Very expensive
EV / EBITDA
11.4x
Fair
Sector 15.4x|S&P 14.5x
PEG
1.44
Fair
Sector 0.23|S&P 0.86
Fair value (reverse DCF)
391.60 USD
Fairly priced
P/E vs its own 5-year history
among the 3% highest valuations
At its historical high
Market cap
45.0Md USD
Financial strength
7.8/10Cash covers 48.4% of the debt, net debt/EBITDA -1.9x.
Net debt / EBITDA
-1.9x
Net cash
Gearing (net debt / equity)
38.15%
Solid
Cash
6.9Md USD
Cash / market cap
15.32%
Very solid
Cash / total debt
48.38%
Solid
Interest coverage
3.8x
Tight
Net debt
7.4Md USD
Equity
19.3Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 380.32 USD
- MM20392.19
- MM50386.51
- MM200289.49
- RSI 1444.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+5.81%
200-day average slope, 3 months
+15.79%
50-day average slope, 1 month
+0.70%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.59 % per day
Volatility change
-34.02%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 7.16 (11) | 9.15 (26) | 162 768 (19) | 2 834 (13) | 886 (7) |
| 2027 | 16.24 (9) | 16.57 (26) | 168 537 (21) | 4 054 (14) | 2 017 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.5 | 7.7 | 2.0Md USD | 28.1x | 6.0 % | 5.3 % | 15.5 % | -3.1x | 9.0 % | 20.2 % | ||
| 2 | SAUD3 | 7.4 | 6.5 | 8.0Md USD | 14.3x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.6 % | 5.3 % | ||
| 3 | UNH | 6.9 | 5.8 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 4 | HQY | 6.7 | 6.0 | 7.5Md USD | 32.6x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.7 % | ||
| 5 | ELV | 6.3 | 5.2 | 86.4Md USD | 17.7x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 22.7 % | ||
| 6 | CNC | 5.9 | 4.8 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 89.2 % | ||
| 7 | HUM | 5.3 | 3.9 | 45.0Md USD | 38.8x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 45.5 % | ||
| 8 | CLOV | 4.8 | 3.8 | 2.4Md USD | Not meaningful (loss) | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 38.3 % | ||
| 9 | MOH | 4.4 | 2.5 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % |
